🇺🇸

US SEC Filing Intelligence

· daily

Insider Trading Pulse — October 01, 2026

**Insider Trading Pulse – October 1, 2026**: The digest captures 50 filings, dominated by routine director compensation (phantom stock, deferred units) and a few high-conviction open-market transactions. Key signals include a $5M insider purchase by Hyperscale Data's Executive Chairman at $0.50/share, a $560K CFO buy at Murphy USA, and a $2.13M CEO sale at an undisclosed company. Notable patterns include heavy insider selling by a CCO/GC (Wang Yanjun, ~$190K across 4 transactions) and multiple large dispositions to issuer (likely tax-related or buyback tenders). Sector-wise, no single theme dominates, but there is a mix of opportunistic buying in small/mid-caps and routine compensation in large caps. No guidance changes were flagged, but the absence of negative revisions suggests stability. The overall sentiment is neutral-to-cautiously-bullish, with selective high-conviction buys outweighing routine sells in dollar terms.

49 high priority 1 medium 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 01, 2026

This digest covers six US SEC filings from October 1, 2026, all within the corporate distress and bankruptcy stream. The dominant theme is a wave of Nasdaq and NYSE delisting actions, with three companies (Lantern Pharma, Gaxos.ai, Getty Images) receiving non-compliance or delisting notices due to market value, bid price, or abnormally low selling price failures. Getty Images has already been suspended and moved to the OTC market, while Lantern Pharma and Gaxos.ai have 180-day cure periods. A fourth company, SKYX Platforms, fell out of compliance due to a board member's death, triggering governance rule violations. NSTS Bancorp completed a cash merger and was voluntarily delisted, representing a clean exit. Nextdoor voluntarily transferred its listing from NYSE to Nasdaq, a non-distressed move. Period-over-period data was limited in these filings, but the concentration of delisting events signals heightened distress in small-cap and micro-cap equities, particularly in the AI and biotech sectors. Insider activity was absent across all filings, and no forward-looking guidance or capital allocation changes were disclosed, limiting trend analysis but amplifying the urgency of the compliance deadlines.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — October 01, 2026

This digest covers 50 high-priority market events from US SEC filings, dominated by a wave of delistings (10+ companies), insolvencies, and M&A completions. The most critical theme is the acceleration of small-cap and SPAC delistings, with 7 companies formally removed from Nasdaq/NYSE in a single week, signaling a severe liquidity and compliance crisis for micro-cap equities. M&A activity is bifurcated: large-scale strategic deals (CenterPoint's $2.62B divestiture, Gentherm/Modine Reverse Morris Trust) are closing successfully, while several SPAC mergers (Ripple/Evernorth, REEcycle) remain contingent on shareholder approvals. A notable cluster of insider-driven defaults and insolvencies in Indian markets (Siti Networks, SecureKloud) highlights ongoing stress in that jurisdiction. The aggregate period-over-period data reveals a clear pattern of asset sales being used to shore up balance sheets (Ashford Hospitality, CenterPoint) while companies like Getty Images and 5E Advanced Materials face existential liquidity threats. The key takeaway for investors is to avoid catching a falling knife in delisting micro-caps and to focus on the high-conviction, value-creating M&A where insiders have skin in the game.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 01, 2026

Today's US market digest reveals a bifurcated landscape: energy and biotech sectors show strong momentum with high-impact catalysts, while financial distress signals emerge in several small caps. Magnolia Oil & Gas's post-acquisition production surge and TotalEnergies' multi-project expansion highlight energy sector growth, while Monte Rosa's Phase 1 data and PolyPid's regulatory progress underscore biotech upside. Conversely, Americas Carmart faces potential restructuring, Transcode Therapeutics triggered a convertible note prepayment, and Pyxis Oncology's funding runway is contingent on warrant exercise. Insider activity is mostly routine (director awards), but notable buys in ASP Isotopes and MFS Municipal Income Trust contrast with sales in Adlai Nortye. Capital allocation trends show a mix of ATM offerings (Chesapeake Utilities), buybacks (Magnolia), and M&A (NSTS Bancorp merger completion). Key upcoming catalysts include PolyPid's PDUFA date (Nov 28), Magnolia's Q3 earnings, and multiple Phase 2 trial initiations in H1 2027.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 01, 2026

The 19 filings in the S&P 500 Consumer Discretionary stream for October 1, 2026, reveal a sector bifurcated between operational resilience and cautious insider sentiment. NIKE's Q1 FY27 results are the standout, showing a mixed picture of revenue decline (-4% reported) and gross margin expansion (+60 bps), alongside a major restructuring program (Pace) targeting $2.5B in savings, which signals a strategic pivot but near-term uncertainty. The bulk of filings are routine director stock awards (Lowe's, Hilton, Marriott) and a small insider sale at Yum! Brands, indicating no broad-based insider buying or selling conviction. A notable pattern is the prevalence of director compensation via phantom stock or deferred stock at Lowe's and Marriott, suggesting a focus on long-term alignment. The only actionable negative signal is the KFC Division CEO's sale at Yum! Brands, which, while small, is executed under a 10b5-1 plan and warrants monitoring. Overall, the sector appears stable but lacks strong bullish catalysts from insider activity, with NIKE's restructuring being the key event to watch for execution risk and potential turnaround.

17 high priority 2 medium 19 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 01, 2026

The five filings for the USA S&P 500 Healthcare stream are dominated by routine insider equity awards and a procedural corporate action, lacking material financial performance data or forward-looking guidance. All insider transactions are non-cash, non-dilutive phantom stock awards to directors and executives at Merck and Pfizer, signaling standard compensation practices rather than conviction buying or selling. The Medtronic filing is a Rule 425 communication regarding a planned exchange offer to separate its MiniMed business, a significant strategic move that could unlock shareholder value but remains procedural at this stage. No period-over-period financial trends, capital allocation changes, or guidance updates were present in any filing, limiting the depth of quantitative synthesis. The overall sentiment across all filings is neutral, with low materiality scores (3-5/10), indicating no immediate actionable signals for investors. The digest focuses on the strategic implications of Medtronic's separation and the benign nature of the insider awards, while flagging the absence of performance data as a key limitation.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — October 01, 2026

The six filings reveal a bifurcated market landscape: two SPACs (Bowen Acquisition Corp and Karman Line Acquisition Corp) show minimal operational substance with declining cash reserves and shareholder deficits, while established operating companies TD SYNNEX and McCormick report strong revenue growth but face margin compression and elevated leverage from M&A. NaturalShrimp is in liquidation with net liabilities of $8.88M, highlighting extreme distress. Key period-over-period trends include TD SYNNEX's 37.7% YoY revenue surge but 60 bps gross margin decline, and McCormick's 127% net income increase over nine months driven by a one-time $866.8M gain, masking a 52.8% drop in Q3 net income. Insider trading activity is absent across all filings, limiting conviction signals. Forward-looking data is sparse, but scheduled events like earnings calls for TD SYNNEX and McCormick present near-term catalysts. Capital allocation patterns show TD SYNNEX investing heavily in working capital (operating cash flow of -$2.08B) while McCormick levered up for a $1.75B acquisition, increasing short-term borrowings 251%.

6 high priority 6 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 01, 2026

This batch of 12 DEF 14A filings, primarily from small-cap and micro-cap companies, paints a picture of a market segment heavily focused on internal governance, equity incentive management, and capital structure adjustments. A dominant theme is the use of shareholder meetings to authorize share increases for equity plans (Akari Therapeutics, Modular Medical) and warrant exercises (HCW Biologics), signaling a reliance on equity-based compensation and financing. The four Lightstone REITs present a highly unusual pattern of back-to-back meetings on the same day, all with near-identical director election proposals, suggesting centralized governance but raising concerns about shareholder oversight. ResMed stands as a clear outlier, showcasing strong operational performance (8% revenue growth, 17% EPS growth, $1.6B FCF) and significant capital return ($1B+ in dividends/buybacks, up >70% YoY), contrasting sharply with the capital-constrained nature of the other filers. Sysco provided a positive tone on AI/tech transformation, but lacked specific financial data. The overall sentiment is neutral-to-cautious, with the primary actionable intelligence centered on ResMed’s strength and the risk of dilution at several smaller firms.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 01, 2026

The IPO pipeline for October 1, 2026, is dominated by SPAC and blank check activity, with REEcycle's $400M business combination and POP Global's $100M IPO highlighting continued appetite for speculative vehicles despite regulatory scrutiny. Uranium Royalty Corp.'s massive 226.7M share resale registration signals potential overhang, while WhiteHawk's S-1 reveals accounting restatements and complex capital structure. VSEE Health's delisting and reverse split represent a distressed situation with high risk. First Internet Bancorp's exchange offer is a routine debt transaction with minimal market impact. The pipeline shows a bifurcation between high-quality resource plays (Uranium Royalty) and speculative SPACs/distressed issuers, with no traditional operating company IPOs in this cohort.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — October 01, 2026

The October 1, 2026 filings show a concentrated listing-status theme: one completed merger and Nasdaq delisting, one voluntary exchange transfer, two Nasdaq compliance notices, one NYSE suspension and OTC migration, and one board-composition deficiency. The most severe developments are Getty Images' immediate NYSE suspension and Lantern Pharma's failure to satisfy the $35 million minimum market value of listed securities requirement. Gaxos.ai faces a sub-$1.00 bid-price deficiency, while SKYX Platforms must rebuild its independent-board and audit-committee composition after the death of a director. NSTS Bancorp represents a completed liquidity event, with shareholders receiving $14.31 per share in cash and approximately $73.7 million in aggregate consideration. Nextdoor's move from NYSE to Nasdaq is operationally neutral but creates a defined October 14, 2026 trading catalyst. No filing supplied revenue, margin, earnings guidance, insider-trading, dividend, buyback, or valuation-comparison data; therefore, the actionable conclusions are driven primarily by regulatory status, cure periods, transaction terms, and trading-liquidity risk rather than operating-performance trends.

6 high priority 6 total filings
· daily

US Executive Officer Management Changes SEC — October 01, 2026

This digest synthesizes 44 enriched SEC filings (Oct 1, 2026) covering US executive and director changes. Key themes include a wave of CEO/CFO successions (e.g., First Merchants, American Vanguard), aggressive board refreshment with tech/AI expertise (Leidos, Omega Healthcare), and governance actions with significant dilution (Aclarion 10x share increase). Notable capital allocation includes a $250M buyback at Choice Hotels and a $1B+ special dividend at Leidos. Risks center on insider selling (Mattel CEO), rising leverage (Omega), and governance overhang (Aclarion). Opportunities emerge from new leadership with strong operational track records and strategic pivots toward high-growth sectors.

44 high priority 44 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 01, 2026

This digest of 44 SEC filings reveals a period of significant board and leadership refreshment across US equities, with a notable concentration of CEO and CFO transitions in the financial services and real estate sectors. While most changes are orderly and neutral, several high-materiality events stand out: the planned CEO retirement at First Merchants Corp after 29 years and 18 acquisitions, the unexpected director resignation at MediaCo Holding without explanation, and the massive 10x authorized share increase at Aethlon Medical. The data shows a clear trend of companies appointing directors with deep operational and AI/technology expertise, particularly at IBM, Roper Technologies, and Vertex, signaling a strategic pivot toward digital transformation. Insider activity is limited but notable, with the Akari Therapeutics CEO receiving a 32% salary increase tied to shareholder-approved equity grants. The overall sentiment is neutral to positive, with most transitions appearing well-planned and designed to strengthen governance and strategic focus.

44 high priority 44 total filings
· daily

USA Insider Trading Pulse — October 01, 2026

The October 1, 2026, insider trading pulse reveals a market dominated by routine director compensation awards (phantom stock, restricted stock units) across large caps like BXP, Ovintiv, and Pfizer, indicating low conviction signals from these events. However, a clear divergence emerges with several high-conviction insider purchases and significant insider selling, providing actionable signals. The most notable bullish signal is the Executive Chairman of Hyperscale Data buying $5M in stock, while the CFO of Xenon Pharmaceuticals made a $560K open-market purchase, signaling strong management confidence. Conversely, the Executive COB of REX American Resources sold $2.13M, and multiple directors at First Seacoast Bancorp engaged in a coordinated disposal of shares to the issuer, likely tied to a corporate action. The period-over-period data from the enriched filings is sparse, limiting trend analysis, but the insider activity itself points to a bifurcated market where insiders are betting heavily on specific turnaround stories while cashing out of others. The most critical development is the massive insider purchase in Hyperscale Data, which could signal a near-term catalyst or undervaluation, while the First Seacoast Bancorp disposals warrant a deep dive into the company's restructuring plans.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 01, 2026

The October 1, 2026, M&A landscape is dominated by a wave of completed transactions, with 7 of 21 filings reporting closed deals, including the transformative Reverse Morris Trust merger between Gentherm and Modine, and CenterPoint Energy's $2.62 billion divestiture of its Ohio gas utility. A notable trend is the use of complex, non-cash consideration structures, such as Inseego's equity and warrant issuance to Nokia and Sadot Group's contingent convertible preferred stock, indicating a shift toward performance-based deal financing. The SPAC sector shows renewed activity, with Armada Acquisition Corp. II securing shareholder approval for its Ripple Labs combination and Launch Two Acquisition Corp. seeking an extension to avoid liquidation, suggesting a potential revival in the blank-check market. However, significant risks persist, including the non-binding nature of several key milestones for Aureus Greenway Holdings and the declining financial performance of Sangoma Technologies, which is being acquired by B. Riley Financial. The overall sentiment is cautiously positive, with 9 filings carrying a positive sentiment, but 5 filings with mixed or neutral outlooks highlight the execution risks inherent in these transactions.

21 high priority 21 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 30, 2026

The four filings present a bifurcated technology sector landscape. Micron's record fiscal 2026 results, driven by a 256% revenue surge to $133.19B and a 40.9 percentage point gross margin expansion, underscore the massive AI-driven demand for memory, yet its flat margin and sequential revenue guidance for Q1 2027 signal a potential peak-cycle slowdown. In contrast, CrowdStrike's CEO insider selling, despite a robust stock price, introduces a note of caution regarding valuation and insider conviction. Qualcomm's filings are routine director stock awards, indicating no change in corporate strategy or management outlook. The overarching theme is one of strong fundamental performance tempered by forward-looking guidance and insider activity that suggest a maturing growth phase, with investors likely to focus on sustainability of AI-driven demand and the potential for margin compression as the cycle normalizes.

3 high priority 1 medium 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 30, 2026

The 7 filings for the NASDAQ-100 stream, all dated September 30, 2026, reveal a bifurcated market landscape. Micron Technology's record fiscal 2026 results, with revenue surging 256% YoY to $133.19 billion and gross margins expanding to 80.7% from 39.8%, underscore the massive AI-driven demand for memory, though guidance for a sequential revenue decline in Q1 2027 signals a potential near-term digestion phase. In contrast, insider activity across Costco and Meta shows consistent selling by top executives, with Costco's EVP and SEVP each selling at $915.93 and Meta's COO executing multiple sales under a 10b5-1 plan, suggesting a cautious stance on valuation. Qualcomm's director stock awards are routine, while Strategy Inc's DEFA14A filing is purely administrative. The overarching theme is a market rewarding fundamental growth (Micron) but with rising insider caution at high valuations, creating a nuanced risk-on/risk-off dynamic. The key portfolio-level pattern is the divergence between operational strength in AI-adjacent hardware and the defensive, profit-taking behavior of insiders in consumer and social media names.

5 high priority 2 medium 7 total filings
· daily

Federal Construction & Infrastructure Contracts — September 30, 2026

The sole contract in this digest is a $346.8 million firm fixed-price award from the Department of State to BL HARBERT INTERNATIONAL LLC for the construction of the New Embassy Compound in Jakarta, Indonesia, with a 12-year performance period (2012-2024). This is a civilian (non-DoD) contract, representing 100% of the aggregate value, and carries a neutral signal strength of 5/10. The dominant theme is long-duration diplomatic infrastructure investment, but the contract's age (awarded in 2012) and the company's private status limit direct public market impact. The highest-conviction signal is the execution risk embedded in the fixed-price structure and the $0 total outlayed, which may indicate payment delays or project stalling. Key watch item: monitor for any modifications or completion milestones, as the contract's end date has passed (September 2024), and the $0 outlayed raises questions about current status.

1 total filings
· daily

New Federal Contractors — September 30, 2026

The two contracts in this digest total $638.1 million in obligations, with zero defense-related awards, underscoring a civilian-focused federal procurement landscape. The Department of State's $346.8 million firm fixed-price contract to BL HARBERT INTERNATIONAL for the Jakarta New Embassy Compound (2012-2024) and the Department of Energy's $291.3 million cost-plus-award-fee contract to KEYLOGIC, LLC for mission execution support (2016-2023) dominate the aggregate. The highest-conviction signal is bullish on KEYLOGIC, given its small business set-aside status and $142.2 million already outlayed, indicating strong revenue recognition. However, the BL HARBERT contract carries high execution risk due to its fixed-price structure and $0 outlayed to date, suggesting potential payment delays or performance issues. Key watch items include option exercises and re-compete timelines for both contracts, as well as any modifications that could signal budget shifts in diplomatic infrastructure or energy technology support.

2 total filings
· daily

Significant Contract Modifications ($10M+) — September 30, 2026

The September 30, 2026 contract modification stream totals $638.2 million across three awards, all from civilian agencies (Department of State, Department of Energy, NASA) with zero defense-related obligations. The dominant theme is long-dated civilian infrastructure and energy R&D, led by BL HARBERT INTERNATIONAL's $346.8 million State Department embassy construction contract (2012-2024) and KEYLOGIC's $291.3 million DOE energy technology support award (2016-2023). The highest-conviction signal is KEYLOGIC's cost-plus-award-fee structure with $142.2 million already outlayed, indicating stable revenue recognition for a small business in a protected set-aside market. However, the stream is heavily weighted toward legacy contracts (average age ~10 years), with Lockheed Martin's $74,981 NASA task order being the only recent award—highlighting a lack of fresh momentum in civilian procurement. Key risk: BL HARBERT's firm-fixed-price structure on a 12-year construction project carries execution risk, especially with $0 outlayed to date, suggesting potential payment delays or project stalling.

3 total filings
· daily

Contract Deobligations Alert — September 30, 2026

The September 30, 2026 deobligation alert stream aggregates $638.2 million in total obligations across three contracts, all civilian (0% defense-related), with an average signal strength of 4.3/10. The dominant theme is long-duration civilian infrastructure and energy support services, led by BL HARBERT INTERNATIONAL LLC's $346.8 million Department of State embassy construction contract (2012-2024) and KEYLOGIC, LLC's $291.3 million Department of Energy mission support award (2016-2023), which together represent 99.9% of total value. The highest-conviction signal is KEYLOGIC's bullish small-business set-aside position in DOE's energy technology services, though its cost-plus structure caps upside. Key risks include BL HARBERT's high fixed-price execution risk with zero outlayed funds and the negligible $74,981 Lockheed Martin NASA task order, which is immaterial to that company's valuation. Watch for option exercises and re-compete announcements for KEYLOGIC post-March 2023 and BL HARBERT's payment status, as $0 outlayed may signal delays or disputes.

3 total filings